Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Represents Underwriters in Cidara IPO

April 20, 2015

NEW YORK — Covington advised the underwriters in the $76.8 million initial public offering of common stock of Cidara Therapeutics, Inc. Shares of Cidara trade on the NASDAQ Global Market under the ticker “CDTX.”

Cidara is a biopharmaceutical company focused on the discovery, development and commercialization of anti-infectives for treatment of diseases inadequately addressed by existing drugs. Cidara plans to use the net proceeds from the offering to fund clinical development and trials of its product candidates and to expand its product pipeline.

The Covington corporate team included partner Eric Blanchard and associates Matt Gehl, Sarah Griffiths and Laura Torre. Assistance was also provided by special counsel Marianne McKeon (FINRA); senior counsel Peter Safir (regulatory); partner Lee Tiedrich, of counsel Natalie Derzko, and associate Priscilla Dodson (IP); and partner Gus Caywood (legal opinion matters).

 

Share this article: